NextCure (NXTC) Competitors $1.30 -0.01 (-0.76%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends NXTC vs. HOOK, KZR, PRTK, BDTX, NLTX, IVA, ABOS, ELUT, FTLF, and IXHLShould you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Hookipa Pharma (HOOK), Kezar Life Sciences (KZR), Paratek Pharmaceuticals (PRTK), Black Diamond Therapeutics (BDTX), Neoleukin Therapeutics (NLTX), Inventiva (IVA), Acumen Pharmaceuticals (ABOS), Elutia (ELUT), FitLife Brands (FTLF), and Incannex Healthcare (IXHL). These companies are all part of the "medical" sector. NextCure vs. Hookipa Pharma Kezar Life Sciences Paratek Pharmaceuticals Black Diamond Therapeutics Neoleukin Therapeutics Inventiva Acumen Pharmaceuticals Elutia FitLife Brands Incannex Healthcare Hookipa Pharma (NASDAQ:HOOK) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, community ranking, earnings, valuation and risk. Is HOOK or NXTC more profitable? NextCure has a net margin of 0.00% compared to Hookipa Pharma's net margin of -86.74%. Hookipa Pharma's return on equity of -33.31% beat NextCure's return on equity.Company Net Margins Return on Equity Return on Assets Hookipa Pharma-86.74% -33.31% -21.65% NextCure N/A -62.50%-53.67% Which has more risk & volatility, HOOK or NXTC? Hookipa Pharma has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, NextCure has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Does the media favor HOOK or NXTC? In the previous week, Hookipa Pharma had 6 more articles in the media than NextCure. MarketBeat recorded 7 mentions for Hookipa Pharma and 1 mentions for NextCure. NextCure's average media sentiment score of 0.00 beat Hookipa Pharma's score of -0.19 indicating that NextCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hookipa Pharma 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral NextCure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings and valuation, HOOK or NXTC? NextCure has lower revenue, but higher earnings than Hookipa Pharma. Hookipa Pharma is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHookipa Pharma$20.13M1.63-$81.58M-$3.72-0.73NextCureN/AN/A-$62.72M-$2.09-0.62 Does the MarketBeat Community prefer HOOK or NXTC? Hookipa Pharma received 11 more outperform votes than NextCure when rated by MarketBeat users. Likewise, 70.54% of users gave Hookipa Pharma an outperform vote while only 64.52% of users gave NextCure an outperform vote. CompanyUnderperformOutperformHookipa PharmaOutperform Votes9170.54% Underperform Votes3829.46% NextCureOutperform Votes8064.52% Underperform Votes4435.48% Do analysts rate HOOK or NXTC? Hookipa Pharma currently has a consensus price target of $38.33, suggesting a potential upside of 1,309.31%. NextCure has a consensus price target of $4.00, suggesting a potential upside of 207.69%. Given Hookipa Pharma's higher possible upside, equities research analysts plainly believe Hookipa Pharma is more favorable than NextCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hookipa Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00NextCure 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in HOOK or NXTC? 63.9% of Hookipa Pharma shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 3.3% of Hookipa Pharma shares are held by insiders. Comparatively, 13.3% of NextCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryHookipa Pharma beats NextCure on 10 of the 16 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get NextCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NXTC vs. The Competition Export to ExcelMetricNextCurePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.69M$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-0.624.8587.8613.46Price / SalesN/A374.821,228.8287.66Price / CashN/A52.5939.5136.27Price / Book0.4810.216.946.30Net Income-$62.72M$153.61M$119.12M$225.93M7 Day Performance-2.99%-2.00%-1.84%-1.32%1 Month Performance-2.99%-7.47%-3.65%0.60%1 Year Performance5.69%31.80%31.64%26.23% NextCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NXTCNextCure4.3842 of 5 stars$1.30-0.8%$4.00+207.7%+4.8%$36.69MN/A-0.6290HOOKHookipa Pharma2.4671 of 5 stars$2.72-2.5%$38.33+1,309.3%-46.4%$33.63M$20.13M-0.7356KZRKezar Life Sciences4.3605 of 5 stars$7.49+1.5%$40.50+440.7%-15.4%$53.85M$7M0.0060Analyst RevisionPRTKParatek Pharmaceuticals0.0195 of 5 stars$2.23+1.8%N/A+0.0%$127.82M$160.27M-2.03268High Trading VolumeBDTXBlack Diamond Therapeutics2.8436 of 5 stars$2.43-4.7%$15.50+537.9%+8.0%$144.29MN/A0.0090Positive NewsNLTXNeoleukin TherapeuticsN/A$15.33-11.0%N/A+30.5%$144.07MN/A-4.9390High Trading VolumeIVAInventiva3.0751 of 5 stars$2.74flat$14.00+410.9%-31.9%$143.79M$18.91M0.00100News CoverageABOSAcumen Pharmaceuticals2.6635 of 5 stars$2.37-0.8%$9.00+279.7%+0.4%$143.59MN/A0.0051Analyst RevisionELUTElutia2.685 of 5 stars$4.38+4.0%$10.00+128.3%+170.4%$143.39M$24.75M0.00180FTLFFitLife Brands4.0645 of 5 stars$31.83+2.3%$40.00+25.7%+59.9%$143.01M$52.70M18.8320Analyst RevisionIXHLIncannex Healthcare1.3552 of 5 stars$2.09-2.8%N/A+132.2%$136.48M$10,000.000.003Gap Up Related Companies and Tools Related Companies HOOK Competitors KZR Competitors PRTK Competitors BDTX Competitors NLTX Competitors IVA Competitors ABOS Competitors ELUT Competitors FTLF Competitors IXHL Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NXTC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
